Table 2.
βIII-Tubulin Expression and Correlation with Neoadjuvant Treatment Response
| Variable | Total | High βIII | Low βIII | Fisher Test P Value | |
|---|---|---|---|---|---|
| n | % | n | n | ||
| Overall | 44 | ||||
| RCB 0–I | 12 | 27 | 6 | 6 | .152 |
| RCB II–III | 32 | 73 | 8 | 24 | |
| ER− | 24 | ||||
| RCB 0–I | 8 | 33 | 5 | 3 | .021 |
| RCB II–III | 16 | 67 | 2 | 14 | |
| ER+ | 20 | ||||
| RCB 0–I | 4 | 20 | 1 | 3 | 1 |
| RCB II–III | 16 | 80 | 6 | 10 | |
| Taxane Treated | 33 | ||||
| RCB 0–I | 11 | 33 | 5 | 6 | .212 |
| RCB II–III | 22 | 67 | 4 | 18 | |
| ER− | 19 | ||||
| RCB 0-I | 7 | 37 | 4 | 3 | .038 |
| RCB II–III | 12 | 63 | 1 | 11 | |
| ER+ | 14 | ||||
| RCB 0–I | 4 | 29 | 1 | 3 | 1 |
| RCB II–III | 10 | 71 | 3 | 7 | |
Abbreviations: ER+ = estrogen receptor positive; ER− = estrogen receptor negative; RCB = residual cancer burden.